Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that the U.S. Food and Drug Administration (FDA) has approved XOCOVA® (ensitrelvir), an oral antiviral, for...
Nestlé Health Science, a global leader in the science of nutrition, and IdB Holding S.p.A. (IdB), a global leader in the production of high potent active pharmaceutical ingredients for the pharmaceutical and the health food industries, announced...
SK bioscience announced that it has signed an agreement with Colombia's state-owned pharmaceutical company VECOL for vaccine technology transfer and local manufacturing cooperation as part of Colombia's national vaccine localization initiative....
LIB Therapeutics Inc. (LIB), a privately-held, biopharmaceutical company with a recently approved novel, monthly, small-dose, third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga), announced results from two oral and two poster...
H. Lundbeck A/S (Lundbeck) announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing authorization for eptinezumab for use in adults with migraine. Migraine is a progressive and debilitating neurological...
BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, announced the signing of a binding Heads of Terms agreement with Wellingto. Zhaotai Therapies Limited (Wellington Zhaotai) under which...
NurtureBio, a new maternal and child wellness company focused on emerging scientific solutions to gut health issues, today announced its official launch and the release of its first product: a synbiotic supplement. This synbiotic features human...
InFocus Clinical Research, the only global, full-service retina specialty contract research organization, announced that Elizabeth Nanouris has joined InFocus as vice president of business operations. Nanouris joins a robust operations team and...
Novo Nordisk announced that starting Monday, May 4, Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US. Ozempic® is the only FDA-approved oral peptide GLP-1 medication for adults with...
Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who...
Rapid Nexus Nanotech Wound Solutions, Inc., a California-based medical technology company, announced it has secured supply contracts with the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) and will begin commercial...
OrthoTrophix, Inc., a privately held biopharmaceutical company, today announced new clinical data demonstrating a significant association between femoral subchondral bone shape, measured by B-score, and meniscal pathology in patients with knee...
Ro, the leading direct-to-patient healthcare company, announced eligible patients can now access Foundayo™ (orforglipron) – Eli Lilly Company's newest oral GLP-1 innovation – on the Ro platform, adding to Ro's already comprehensive formulary of...
A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A...
ulrich medical USA is pleased to announce the appointment of Alissa Calaway, RN, MSN, as Director of U.S. Clinical Affairs. Alongside this leadership appointment, the company is launching a U.S.-based Clinical Research Program designed to generate...
ARUP Laboratories, a leader in diagnostic medicine and the largest nonprofit reference laboratory in the U.S., announced the launch of a new Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other...
P-Cure, a supplier of compact, gantry-less proton therapy systems, announced the first-ever prospective clinical results demonstrating the feasibility, safety, and early efficacy of gantry-less upright proton therapy for lung cancer...
Celltrion, Inc. announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response in most Crohn’s disease (CD) and ulcerative colitis...
HanchorBio, Inc. a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing...
Alamar Biosciences, Inc. a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay. This innovative solution enables...
